Cargando…

Potential plasma biomarkers at low altitude for prediction of acute mountain sickness

BACKGROUND: Ascending to high altitude can induce a range of physiological and molecular alterations, rendering a proportion of lowlanders unacclimatized. The prediction of acute mountain sickness (AMS) prior to ascent to high altitude remains elusive. METHODS: A total of 40 participants were enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Haoran, Wang, Qi, Li, Tao, Chen, Jingwen, Zhang, Chao, Xu, Ying, Chang, Qing, Li, Hangyi, Sun, Weiqiang, Han, Ruidi, Wang, Chi, Wang, Chengbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569122/
https://www.ncbi.nlm.nih.gov/pubmed/37841248
http://dx.doi.org/10.3389/fimmu.2023.1237465
_version_ 1785119496281784320
author Guo, Haoran
Wang, Qi
Li, Tao
Chen, Jingwen
Zhang, Chao
Xu, Ying
Chang, Qing
Li, Hangyi
Sun, Weiqiang
Han, Ruidi
Wang, Chi
Wang, Chengbin
author_facet Guo, Haoran
Wang, Qi
Li, Tao
Chen, Jingwen
Zhang, Chao
Xu, Ying
Chang, Qing
Li, Hangyi
Sun, Weiqiang
Han, Ruidi
Wang, Chi
Wang, Chengbin
author_sort Guo, Haoran
collection PubMed
description BACKGROUND: Ascending to high altitude can induce a range of physiological and molecular alterations, rendering a proportion of lowlanders unacclimatized. The prediction of acute mountain sickness (AMS) prior to ascent to high altitude remains elusive. METHODS: A total of 40 participants were enrolled for our study in the discovery cohort, and plasma samples were collected from all individuals. The subjects were divided into severe AMS-susceptible (sAMS) group, moderate AMS-susceptible (mAMS) group and non-AMS group based on the Lake Louise Score (LLS) at both 5000m and 3700m. Proteomic analysis was conducted on a cohort of 40 individuals to elucidate differentially expressed proteins (DEPs) and associated pathways between AMS-susceptible group and AMS-resistant group at low altitude (1400m) and middle high-altitude (3700m). Subsequently, a validation cohort consisting of 118 individuals was enrolled. The plasma concentration of selected DEPs were quantified using ELISA. Comparative analyses of DEPs among different groups in validation cohort were performed, followed by Receiver Operating Characteristic (ROC) analysis to evaluate the predictive efficiency of DEPs for the occurrence of AMS. RESULTS: The occurrence of the AMS symptoms and LLS differed significantly among the three groups in the discovery cohort (p<0.05), as well as in the validation cohort. Comparison of plasma protein profiles using GO analysis revealed that DEPs were primarily enriched in granulocyte activation, neutrophil mediated immunity, and humoral immune response. The comparison of potential biomarkers between the sAMS group and non-AMS group at low altitude revealed statistically higher levels of AAT, SAP and LTF in sAMS group (p=0.01), with a combined area under the curve(AUC) of 0.965. Compared to the mAMS group at low altitude, both SAP and LTF were found to be significantly elevated in the sAMS group, with a combined AUC of 0.887. HSP90-α and SAP exhibited statistically higher levels in the mAMS group compared to the non-AMS group at low altitude, with a combined AUC of 0.874. CONCLUSION: Inflammatory and immune related biological processes were significantly different between AMS-susceptible and AMS-resistant groups at low altitude and middle high-altitude. SAP, AAT, LTF and HSP90-α were considered as potential biomarkers at low altitude for the prediction of AMS.
format Online
Article
Text
id pubmed-10569122
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105691222023-10-13 Potential plasma biomarkers at low altitude for prediction of acute mountain sickness Guo, Haoran Wang, Qi Li, Tao Chen, Jingwen Zhang, Chao Xu, Ying Chang, Qing Li, Hangyi Sun, Weiqiang Han, Ruidi Wang, Chi Wang, Chengbin Front Immunol Immunology BACKGROUND: Ascending to high altitude can induce a range of physiological and molecular alterations, rendering a proportion of lowlanders unacclimatized. The prediction of acute mountain sickness (AMS) prior to ascent to high altitude remains elusive. METHODS: A total of 40 participants were enrolled for our study in the discovery cohort, and plasma samples were collected from all individuals. The subjects were divided into severe AMS-susceptible (sAMS) group, moderate AMS-susceptible (mAMS) group and non-AMS group based on the Lake Louise Score (LLS) at both 5000m and 3700m. Proteomic analysis was conducted on a cohort of 40 individuals to elucidate differentially expressed proteins (DEPs) and associated pathways between AMS-susceptible group and AMS-resistant group at low altitude (1400m) and middle high-altitude (3700m). Subsequently, a validation cohort consisting of 118 individuals was enrolled. The plasma concentration of selected DEPs were quantified using ELISA. Comparative analyses of DEPs among different groups in validation cohort were performed, followed by Receiver Operating Characteristic (ROC) analysis to evaluate the predictive efficiency of DEPs for the occurrence of AMS. RESULTS: The occurrence of the AMS symptoms and LLS differed significantly among the three groups in the discovery cohort (p<0.05), as well as in the validation cohort. Comparison of plasma protein profiles using GO analysis revealed that DEPs were primarily enriched in granulocyte activation, neutrophil mediated immunity, and humoral immune response. The comparison of potential biomarkers between the sAMS group and non-AMS group at low altitude revealed statistically higher levels of AAT, SAP and LTF in sAMS group (p=0.01), with a combined area under the curve(AUC) of 0.965. Compared to the mAMS group at low altitude, both SAP and LTF were found to be significantly elevated in the sAMS group, with a combined AUC of 0.887. HSP90-α and SAP exhibited statistically higher levels in the mAMS group compared to the non-AMS group at low altitude, with a combined AUC of 0.874. CONCLUSION: Inflammatory and immune related biological processes were significantly different between AMS-susceptible and AMS-resistant groups at low altitude and middle high-altitude. SAP, AAT, LTF and HSP90-α were considered as potential biomarkers at low altitude for the prediction of AMS. Frontiers Media S.A. 2023-09-28 /pmc/articles/PMC10569122/ /pubmed/37841248 http://dx.doi.org/10.3389/fimmu.2023.1237465 Text en Copyright © 2023 Guo, Wang, Li, Chen, Zhang, Xu, Chang, Li, Sun, Han, Wang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Guo, Haoran
Wang, Qi
Li, Tao
Chen, Jingwen
Zhang, Chao
Xu, Ying
Chang, Qing
Li, Hangyi
Sun, Weiqiang
Han, Ruidi
Wang, Chi
Wang, Chengbin
Potential plasma biomarkers at low altitude for prediction of acute mountain sickness
title Potential plasma biomarkers at low altitude for prediction of acute mountain sickness
title_full Potential plasma biomarkers at low altitude for prediction of acute mountain sickness
title_fullStr Potential plasma biomarkers at low altitude for prediction of acute mountain sickness
title_full_unstemmed Potential plasma biomarkers at low altitude for prediction of acute mountain sickness
title_short Potential plasma biomarkers at low altitude for prediction of acute mountain sickness
title_sort potential plasma biomarkers at low altitude for prediction of acute mountain sickness
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569122/
https://www.ncbi.nlm.nih.gov/pubmed/37841248
http://dx.doi.org/10.3389/fimmu.2023.1237465
work_keys_str_mv AT guohaoran potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT wangqi potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT litao potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT chenjingwen potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT zhangchao potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT xuying potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT changqing potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT lihangyi potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT sunweiqiang potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT hanruidi potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT wangchi potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness
AT wangchengbin potentialplasmabiomarkersatlowaltitudeforpredictionofacutemountainsickness